Fragment-based drug design (FBDD) has led to a revolution in contemporary drug discovery, facilitating a bottom-up approach to the identification and evolution of bioactive small molecules into viable ...
Researchers unveil the first 48-channel high-throughput SPR platform, enabling primary screening of large molecular libraries with high-resolution binding data, 12-fold higher throughput, and minimal ...
Vega instrument combines ultra-high-throughput, data quality, and assay flexibility for both traditional and AI-based drug discoveryEnables ...
Short-term thermal stability testing is vital for analyzing a compound’s resistance to thermal stress, which is crucial for estimating shelf life and preserving efficacy. Differential Scanning ...
Revvity offers comprehensive solutions designed to help accelerate laboratory workflows, assisting researchers meet targets faster and bring new therapies to market sooner. Our integrated approach ...
Pharmaceutical Technology on MSN
RNA-targeting small molecules: A new frontier of drug discovery
With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology ...
A novel optogenetic screening platform enables control over previously intractable biological systems. Using the screening platform, scientists have been able to selectively activate the integrated ...
Small Molecule Drug Development Core Facility (SMDD Core) has the automation equipment, libraries, and experienced personnel to support a wide range of assay ...
From antibiotic resistance to emerging viral threats, the global demand for new medicines is intensifying, yet traditional drug discovery pipelines remain slow and expensive. A new scientific review ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results